Can early combo therapy shield kidneys in septic shock?
NCT ID NCT07418541
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether giving intravenous fluids and a blood-pressure-raising drug (norepinephrine) together early can prevent acute kidney injury in adults with septic shock. Researchers will treat 100 patients in the ICU or emergency department and monitor kidney function and blood pressure changes. The goal is to see if this early combination approach reduces kidney damage compared to standard timing.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
norepinephrine (noradrenaline) and crystalloid fluids
What this could lead to
If successful, this could show that giving fluids and a blood-pressure drug together early helps prevent kidney damage in septic shock patients.
What could go wrong
This is a small, early-stage study (100 people) with no control group, so results may not be definitive. The approach is already standard care, so benefits may be modest.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE KIDNEY INJURY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••